Brain tumours encompass a heterogeneous collection of neoplasms, traditionally classified by histopathological criteria. In 2016, the WHO published an updated classification that, for the first time, defines brain tumour types according to integrated histological and molecular parameters. Furthermore, clinical trial results were reported that inform therapeutic decision-making in diffuse gliomas.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803–820 (2016).
van den Bent, M. J. Chemotherapy for low-grade glioma: when, for whom, which regimen? Curr. Opin. Neurol. 28, 633–938 (2015).
Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344–1355 (2016).
Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521–1532 (2016).
Reijneveld, J. C. et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1533–1542 (2016).
van den Bent, M. J. et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: an intergroup trial [abstract]. J. Clin. Oncol. 34 (Suppl.), LBA2000 (2016).
Wirsching, H. G., Happold, C., Roth, P. & Weller, M. Management of diffusely infiltrating glioma in the elderly. Curr. Opin. Oncol. 27, 502–509 (2015).
Perry, J. R. et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062–22061, TROG 08.02, NCT00482677) [abstract]. J. Clin. Oncol. 34 (Suppl.), LBA2 (2016).
Phillips, A. C. et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol. Cancer Ther. 15, 661–669 (2016).
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A. & Sampson, J. H. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11, 504–514 (2015).
M.P. has received research support from Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche, and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche and Astra Zeneca. C.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Preusser, M., Marosi, C. Advances in brain tumour classification and therapy. Nat Rev Neurol 13, 71–72 (2017). https://doi.org/10.1038/nrneurol.2017.3
This article is cited by
In Vitro Reconstruction of Brain Tumor Microenvironment
BioChip Journal (2019)
Dendrimer-based magnetic resonance imaging agents for brain cancer
Science China Materials (2018)